Abstract
Aims: Ovarian cancer is the deadliest of all gynecologic cancers because of its late diagnosis and poor treatment outcomes. This study aimed to identify potential molecular signatures associated with biological processes that are implicated in epithelial ovarian cancer (EOC). Methods: Expression profiling was carried out on 16 fresh frozen EOC and normal ovarian tissue samples using the Illumina Whole Genome DASL assay (cDNA-mediated annealing, selection, extension and ligation). The differentially expressed genes were analyzed using the GeneSpring GX11.5 and Pathway Studio 8.0 software. The microarray results were validated using the immunohistochemistry analyses. Results: Unpaired t-test identified 652 (270 up- and 382 downregulated) significant differentially expressed genes (P < 0.001 and fold change ≥2.0). Hierarchical clustering analysis displayed a distinct separation of cancer and normal samples. Gene set enrichment analysis identified alterations in the expression of genes associated with cancer development and progression. Positive immunostaining of claudin-7, ephrin receptor A1 and Forkhead Box M1 in EOC was consistent with the upregulation of these genes in the microarray result. However, the positive immunostaining of fibroblast growth factor-7 in cancer tissues was not in accordance with the downregulation of this gene in the microarray result. Conclusion: These results identify significant genes and their related biological processes which may contribute to the better understanding of development and progression of epithelial ovarian cancer.
| Original language | English |
|---|---|
| Pages (from-to) | e259-e268 |
| Journal | Asia-Pacific Journal of Clinical Oncology |
| Volume | 12 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 1 Jun 2016 |
Fingerprint
Keywords
- biological process
- epithelial ovarian cancer
- gene expression profiling
- immunohistochemistry
- microarray
ASJC Scopus subject areas
- Oncology
Cite this
Potential molecular signatures in epithelial ovarian cancer by genome wide expression profiling. / Wong, Yin Ling; Dali, Ahmad Zailani Hatta Mohd; Mohamed Rose, Isa; A. Jamal, A. Rahman; Mohd Mokhtar, Norfilza.
In: Asia-Pacific Journal of Clinical Oncology, Vol. 12, No. 2, 01.06.2016, p. e259-e268.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Potential molecular signatures in epithelial ovarian cancer by genome wide expression profiling
AU - Wong, Yin Ling
AU - Dali, Ahmad Zailani Hatta Mohd
AU - Mohamed Rose, Isa
AU - A. Jamal, A. Rahman
AU - Mohd Mokhtar, Norfilza
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Aims: Ovarian cancer is the deadliest of all gynecologic cancers because of its late diagnosis and poor treatment outcomes. This study aimed to identify potential molecular signatures associated with biological processes that are implicated in epithelial ovarian cancer (EOC). Methods: Expression profiling was carried out on 16 fresh frozen EOC and normal ovarian tissue samples using the Illumina Whole Genome DASL assay (cDNA-mediated annealing, selection, extension and ligation). The differentially expressed genes were analyzed using the GeneSpring GX11.5 and Pathway Studio 8.0 software. The microarray results were validated using the immunohistochemistry analyses. Results: Unpaired t-test identified 652 (270 up- and 382 downregulated) significant differentially expressed genes (P < 0.001 and fold change ≥2.0). Hierarchical clustering analysis displayed a distinct separation of cancer and normal samples. Gene set enrichment analysis identified alterations in the expression of genes associated with cancer development and progression. Positive immunostaining of claudin-7, ephrin receptor A1 and Forkhead Box M1 in EOC was consistent with the upregulation of these genes in the microarray result. However, the positive immunostaining of fibroblast growth factor-7 in cancer tissues was not in accordance with the downregulation of this gene in the microarray result. Conclusion: These results identify significant genes and their related biological processes which may contribute to the better understanding of development and progression of epithelial ovarian cancer.
AB - Aims: Ovarian cancer is the deadliest of all gynecologic cancers because of its late diagnosis and poor treatment outcomes. This study aimed to identify potential molecular signatures associated with biological processes that are implicated in epithelial ovarian cancer (EOC). Methods: Expression profiling was carried out on 16 fresh frozen EOC and normal ovarian tissue samples using the Illumina Whole Genome DASL assay (cDNA-mediated annealing, selection, extension and ligation). The differentially expressed genes were analyzed using the GeneSpring GX11.5 and Pathway Studio 8.0 software. The microarray results were validated using the immunohistochemistry analyses. Results: Unpaired t-test identified 652 (270 up- and 382 downregulated) significant differentially expressed genes (P < 0.001 and fold change ≥2.0). Hierarchical clustering analysis displayed a distinct separation of cancer and normal samples. Gene set enrichment analysis identified alterations in the expression of genes associated with cancer development and progression. Positive immunostaining of claudin-7, ephrin receptor A1 and Forkhead Box M1 in EOC was consistent with the upregulation of these genes in the microarray result. However, the positive immunostaining of fibroblast growth factor-7 in cancer tissues was not in accordance with the downregulation of this gene in the microarray result. Conclusion: These results identify significant genes and their related biological processes which may contribute to the better understanding of development and progression of epithelial ovarian cancer.
KW - biological process
KW - epithelial ovarian cancer
KW - gene expression profiling
KW - immunohistochemistry
KW - microarray
UR - http://www.scopus.com/inward/record.url?scp=85028256278&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028256278&partnerID=8YFLogxK
U2 - 10.1111/ajco.12182
DO - 10.1111/ajco.12182
M3 - Article
VL - 12
SP - e259-e268
JO - Asia-Pacific Journal of Clinical Oncology
JF - Asia-Pacific Journal of Clinical Oncology
SN - 1743-7555
IS - 2
ER -